Topics: The US recovery; The flood of money and market returns; Globalization lives; Reducing COVID mortality through vascular treatments; Realistic timetables for never-been-done before vaccines; Sweden’s COVID experiment is not what you think

Note: the next Eye on the Market will be our tenth annual energy paper

The bounce. Last week’s payroll report showed an increase of 2.5 mm jobs, auto sales rose 40% in one month, unemployment claims dropped below 2 mm and mortgage applications are up 60% from April lows. We’re even seeing a rebound in short term vacation rental bookings, which after falling in half by April, have risen above pre-COVID levels. The contour of these changes are not a surprise, since an imposed slowdown is less “real” than an organic one; but the speed and magnitude are impressive. On March 20, I wrote this: “I agree with anyone who says it is likely to get worse before it gets better, certainly from an economic perspective. But if you were to ask me what the world will feel like a year from now, I would say 70%-80% back to normal”. I got some grief at the time since it was perceived as too optimistic (which I’m rarely accused of being); last week was a first important step on the way to that kind of outcome.

Another chart we’re tracking closely looks at changes in overall US consumer spending, and at changes in “COVID-sensitive in-person social distancing” spending, which refers to transactions at retail stores, restaurants, hotels, amusement parks, theatres, etc. Both categories are recovering, and in states with low COVID infection rates, COVID-sensitive spending is recovering at an even faster pace. Yes, levels are still down 30% vs last year, but as in most cycles, it’s the rate of change that matters more for investors. Two months after the worst pandemic in 100 years, to me, this first chart is an encouraging one.

A second infection wave could reverse spending trends if they were severe enough to prompt governors to reimpose lockdowns. So far, the only second waves we’re seeing according to our methods are shown on the right. Do they look like second waves to you? The definition is subjective, similar to Supreme Court Justice Potter Stewart’s description of obscenity in 1964 (“I know it when I see it”). These look like second waves to me (of different sizes, obviously), but others may disagree. Either way, median state ICU utilization rates have fallen to 7% and median state hospital bed utilization rates have fallen to 52%, indicating higher levels of healthcare capacity when/if second waves occur.
The flood of money and market returns

Even after incorporating the positive economic news on the prior page, it’s impossible to divorce the recent rally in equity and credit markets from the flood of money from the Fed. The first chart speaks for itself. On the right, the table shows how the Fed has been able to reverse most of the damage in many credit markets since peak spread levels.

Another downstream impact of the flood of money: US high yield bonds recently recorded the three largest weekly inflows on record; the $35 billion of inflows were equal to **18% of all high yield bonds under management**. You can also see the impact of ample liquidity on rising P/E multiples of COVID “victim” sectors (gold line and bars in the charts below). The performance of the resilient blue sectors makes sense to me, and they represent around 2/3 of S&P 500 market cap. But the recovery of the victim sectors is pricing in an even more rapid recovery than the one occurring now, and suggests that many investors are searching for any possible return now that cash and bond yields have been eviscerated (again) by the Fed.
Globalization may be hard to kill

You might see globalization as a positive force or as a virus; either way, it may be hard to kill. The charts below help explain why. While S&P 500 manufacturer profit margins risen since the early 2000’s, only one fifth of the increase was linked to wage savings resulting from offshore production. According to Empirical Research Partners, the rest resulted from greater domestic efficiencies (from capex and software), declining tax rates, the use of tax havens and declining interest rates. As a result, a partial reversal of globalization might not have as large an impact on S&P profit margins as you might think.

Also: a lot of US multinational offshore production occurs to meet local demand; tariffs and stricter rules on affiliate taxation will do little to change this. Finally, while the US has a large trade deficit with China, US multinational sales within China are just as large. The Trump administration may adopt high-profile policies to curb access to US technology and theft of US intellectual property, but China has leverage of its own with respect to the ability of US multinationals to do business there. If that’s the case, US actions may have more bark than bite, and the globalization of profit margins may be here for a while longer.

---

1 Proposals from the Senate, FCC, Dept’s of Defense/Commerce and the White House include: ban on Chinese ADRs from US exchanges based on audit quality; restrict Huawei’s access to semiconductor designs/chipsets; freeze assets of Chinese policymakers involved with loss of Hong Kong autonomy; “Show cause” orders for Chinese telecom companies operating in the US that are subject to ownership/control of the Chinese gov’t; Federal retirement plans should exclude Chinese equities from benchmark; Require US healthcare companies to disclose China product content; Screen out Chinese applicants who enter US academic institutions under false pretense; Restrict issuance of Chinese visas for science and engineering students; Restrict US exports to China of technology classified as having potential military use.
What if COVID is also a vascular disease and not just a pulmonary one?
The potential benefits of anticoagulants, statins and ACE inhibitors for infected patients

The understanding of COVID’s impact on the body is still evolving. Healthcare professionals have noticed unconnected vascular phenomena that aren’t seen with SARS-CoV-1 or H1N1. Medical directors at Harvard’s Brigham and Women’s Hospital believe that COVID is a “vasculotropic” disease, and that SARS-CoV-2 can infect endothelial cells that line the inside of blood vessels. These cells protect the cardiovascular system and release proteins that influence everything from blood clotting to immune responses.

- Damage to endothelial cells causes inflammation in blood vessels, which can cause accumulated plaque to rupture, causing a heart attack. Blood vessel damage could also explain why people with pre-existing conditions like high blood pressure, high cholesterol, diabetes, and heart disease are at a higher risk for severe complications from a virus that’s supposed to just infect the lungs. All of those diseases cause endothelial cell damage, and additional damage in blood vessels caused by COVID could result in more severe complications and death.

- This theory could also explain why ventilation often isn’t enough to help patients breathe better. Moving air into the lungs via ventilation can help, but the exchange of oxygen and carbon dioxide in the blood is just as important to provide the rest of the body with oxygen; that requires healthy blood vessels in and around the lungs.

- If COVID is in fact a vascular disease, there are existing drugs that might help protect against endothelial cell damage. Potential solutions could include ACE inhibitors and statins. In a New England Journal of Medicine study of 9,000 people with COVID, the use of statins and ACE inhibitors were linked to higher rates of survival.

- Similarly, a May report in the Journal of the American College of Cardiology analyzed medical records of 2,773 COVID patients in NYC hospitals. The study was initiated after doctors realized that COVID can result in life-threatening blood clots. Notable findings: survival rates for intubated patients treated with anticoagulants were 71% compared to 37% for those who were not.

---

2 “Endothelial cell infection and endotheliitis in COVID-19”, Z. Varga et al. Department of Pathology and Molecular Pathology, University Hospital Zurich. April 20, 2020

3 “Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19”, M. Mehra et al. Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School. May 8, 2020

4 “Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19”, I. Paranjpe et al. Journal of the American College of Cardiology. May 2020
COVID vaccines: be realistic about timetables for never-been-done before approaches

I’m trying to be both optimistic and realistic about chances for a vaccine, particularly as early as 2021, given methods vaccine companies are using to provoke an antibody response to the virus. See the table below; many vaccine candidates you read about in the press are based on methods #3 and #4, which have never been approved for use in the US, Europe or other developed countries. There’s a lot of optimism around clinical trials underway, which we discuss in detail in Section #4 of our online virus portal. But we need to keep in mind that many companies are traveling down new roads in search of a vaccine, which raises the bar for Phase III results and eventual approval.

<table>
<thead>
<tr>
<th>Type</th>
<th>Method of provoking an antibody response to SARS-CoV-2</th>
<th>Select candidates</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>A live but weakened coronavirus that will infect cells and cause them to make viral proteins</td>
<td>Sinovac/Dynavax</td>
</tr>
<tr>
<td>2</td>
<td>A “killed” coronavirus that will get recognized as foreign matter in the blood</td>
<td>CanSino, Oxford, J&amp;J, Merck/Themis</td>
</tr>
<tr>
<td>3*</td>
<td>A different virus (human or ape adenovirus, measles, etc) that is engineered to include genetic components coding for the SARS-CoV-2 spike proteins, which causes the body to then produce them</td>
<td>CanSino, Oxford, J&amp;J, Merck/Themis</td>
</tr>
<tr>
<td>4**</td>
<td>DNA or RNA that will be taken up by cells and will cause them to make coronavirus proteins</td>
<td>Moderna, Innovio, BioNTech/Pfizer</td>
</tr>
<tr>
<td>5</td>
<td>Coronavirus proteins themselves, produced industrially in outside cell cultures, which will be recognized as foreign matter in the blood</td>
<td>GlaxoSmithKline/Sanofi, Novavax</td>
</tr>
</tbody>
</table>

* No adenoviral vector vaccines have yet demonstrated that they can prevent disease in humans. China has approved an adenoviral vector vaccine for Ebola, but Phase II studies did not prove that it prevents Ebola infection. J&J’s adenoviral vector vaccine for Ebola is currently under review in Europe.

** There are no approved DNA or RNA vaccines yet, and neither have ever been tested before COVID in a large scale clinical trial.

Through a glass, darkly: the real reasons for Sweden's unorthodox COVID experiment

These charts don’t look good for Sweden’s COVID experiment, particularly since Sweden has actually performed many fewer COVID tests per person than Denmark, Finland and Norway.

Over a month ago, researchers from Swedish universities and research institutes began leveling criticism at the Swedish Public Health Agency for their coronavirus strategy, arguing that elected politicians should intervene with “swift and radical measures”. Critics cited the Agency claiming on four occasions that the spread of infection had levelled out, despite evidence to the contrary. Nevertheless, Sweden has continued with its more lax approach to the virus, which began with a policy expert view that evidence in favor of lockdowns, hand washing and school closings was weak.

The most interesting thing I’ve read about why this has happened cites Sweden’s “epistocracy”, which refers to a country in which government-appointed experts decide on a course of action, after which politicians cannot tell government agencies what to do. Furthermore, the Swedish constitution lacks a provision which allows for proclamation of a state of emergency in peacetime, preventing the government from substantially restricting personal mobility in the first place.

Given this context, I’m not sure that the charts above, no matter how bad they got, would prompt the Swedish Public Health Agency to change course. In any case, I think we should stop thinking of Sweden as a place that made a choice based on epidemiological evidence; we should think of Sweden instead as a place that made a decision based on its constitutional framework and public policy history.

---

5 Forbes, April 14, 2020

6 Sweden followed through on its policy expert recommendations: Sweden’s maximum Oxford Stringency Index score is 58, compared to 76 for Finland, 84 for Denmark and 85 for Norway.

7 “The Swedish Exception?”, Tony Hackley, London School of Economics, April 23, 2020
This report uses rigorous security protocols for selected data sourced from Chase credit and debit card transactions to ensure all information is kept confidential and secure. All selected data is highly aggregated and all unique identifiable information—including names, account numbers, addresses, dates of birth, and Social Security Numbers—is removed from the data before the report’s author receives it.

**NOT FOR RETAIL DISTRIBUTION:** This communication has been prepared exclusively for institutional, wholesale, professional clients and qualified investors only, as defined by local laws and regulations.

This material is for information purposes only. The views, opinions, estimates and strategies expressed herein constitutes Michael Cembalest’s judgment based on current market conditions and are subject to change without notice, and may differ from those expressed by other areas of J.P. Morgan. This information in no way constitutes J.P. Morgan Research and should not be treated as such.

This is a promotional document and is intended to report solely on investment strategies and opportunities identified by J.P. Morgan Asset Management and as such the views contained herein are not to be taken as advice or a recommendation to buy or sell any investment or interest thereto. This document is confidential and intended only for the person or entity to which it has been provided. Reliance upon information in this material is at the sole discretion of the reader. The material was prepared without regard to specific objectives, financial situation or needs of any particular receiver. Any research in this document has been obtained and may have been acted upon by J.P. Morgan Asset Management for its own purpose. The results of such research are being made available as additional information and do not necessarily reflect the views of J.P. Morgan Asset Management. This presentation is qualified in its entirety by the offering memorandum, which should be carefully read prior to any investment in a fund. The purchase of shares of a fund is suitable only for sophisticated investors for whom an investment in such fund does not constitute a complete investment program and who fully understand and are willing to assume the risks involved in such fund’s investment program. An investment in the funds involves a number of risks. For a description of the risk factors associated with an investment in a fund, please refer to the section discussing risk factors in the offering memorandum (available upon request). Shares of the funds are not deposits, obligations of, or endorsed or guaranteed by, JPMorgan Chase Bank, NA or any other bank and are not insured by the FDIC, the Federal Reserve Board or any other government agency. Any forecasts, figures, opinions, statements of financial market trends or investment techniques and strategies expressed are those of J.P. Morgan Asset Management, unless otherwise stated, as of the date of issuance. They are considered to be reliable at the time of production, but no warranty as to the accuracy and reliability or completeness in respect of any error or omission is accepted, and may be subject to change without reference or notification to you. Investments in Alternative Investment Funds (AIFs) involves a high degree of risks, including the possible loss of the original amount invested. The value of investments and the income from them may fluctuate in accordance with market conditions and taxation agreements. Changes in exchange rates may have an adverse effect on the value, price or income of the products or underlying investment. Both past performance and yields are not reliable indicators of current and future results. There is no guarantee that any forecast will come to pass. Any investment decision should be based solely on the basis of any applicable local offering documents such as the prospectus, annual report, semi-annual report, private placement or offering memorandum. For further information, any questions and for copies of the offering material you can contact your usual J.P. Morgan Asset Management representative. Any reproduction, retransmission, dissemination or other unauthorized use of this document or the information contained herein by any person or entity without the express prior written consent of J.P. Morgan Asset Management is strictly prohibited.

J.P. Morgan Asset Management is the brand for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide. To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our privacy policies at [https://am.jpmorgan.com/globalprivacy](https://am.jpmorgan.com/globalprivacy).

This communication is issued by the following entities:

In the United States, by J.P. Morgan Investment Management Inc. or J.P. Morgan Alternative Asset Management, Inc., both regulated by the Securities and Exchange Commission; in Latin America, for intended recipients’ use only, by local J.P. Morgan entities, as the case may be; in Canada, for institutional clients’ use only, by JPMorgan Asset Management (Canada) Inc., which is a registered Portfolio Manager and Exempt Market Dealer in all Canadian provinces and territories except the Yukon and is also registered as an Investment Fund Manager in British Columbia, Ontario, Quebec and Newfoundland and Labrador. In the United Kingdom, by JPMorgan Asset Management (UK) Limited, which is authorized and regulated by the Financial Conduct Authority; in other European jurisdictions, by JPMorgan Asset Management (Europe) S.à r.l. In Asia Pacific ("APAC"), by the following issuing entities and in the respective jurisdictions in which they are primarily regulated: JPMorgan Asset Management (Asia Pacific) Limited, or JPMorgan Funds (Asia) Limited, or JPMorgan Asset Management Real Assets (Asia) Limited, each of which is regulated by the Securities and Futures Commission of Hong Kong; JPMorgan Asset Management (Singapore) Limited (Co. Reg. No. 197601586K), which this advertisement or publication has not been reviewed by the Monetary Authority of Singapore; JPMorgan Asset Management (Taiwan) Limited; JPMorgan Asset Management (Japan) Limited, which is a member of the Investment Trusts Association, Japan, the Japan Investment Advisers Association, Type II Financial Instruments Firms Association and the Japan Securities Dealers Association and is regulated by the Financial Services Agency (registration number “Kanto Local Finance Bureau (Financial Instruments Firm) No. 330”); in Australia, to wholesale clients only as defined in section 761A and 761G of the Corporations Act 2001 (Commonwealth), by JPMorgan Asset Management (Australia) Limited (ABN 55143832080) (AFSL 376919).

**For U.S. only:** If you are a person with a disability and need additional support in viewing the material, please call us at 1-800-343-1113 for assistance.

Copyright 2020 JPMorgan Chase & Co. All rights reserved.